FDA clearance, panel choice, accuracy, on-site speed and supplier reliability for compliant workplace programs.

Cancer Check Labs, creator of CancerCheck, a one-of-a-kind multi-cancer early detection (MCED) test, has announced a strategic partnership wit ...

Natera, Inc. , a global leader in cell-free DNA and precision medicine, today announced that the U.S. Food and Drug Administration (FDA) has approved Signatera CDx as a companion diagnostic (CDx) for ...

Reward Picks Lucid Diagnostics (NASDAQ:LUCD) reported first-quarter 2026 EsoGuard test volume above its pre-Medicare target range, while management ...

Progressing toward commercialization with third-party head-to-head data publications and GALACTIC registry study engagementNortheast kidney ...

EarlyDiagnostics (EarlyDx) announced PNAS validation of its MethylScan™ platform for multi-disease detection from a single blood sample.

GRAIL, Inc. , a healthcare company whose mission is to detect cancer early when it can be cured, today reported business and financial results for the first quarter of ...

Achieved record total revenue of $17.3 million, an increase of 12% compared to first quarter 2025. Grew AVISE CTD test volume 10% compared to first quarter 2025. Expanded AVISE CTD ...

Q1 Galleri® Revenue Grew 37% Year-Over-Year to $39.8 Million, and Test Volume Increased 50% to More Than 56,000 Announced Plans to Integrate the Galleri Test Into Epic ...

CyPath® Lung cancer diagnostic unit sales rise 146% year-over-yearGrowth expected to accelerate throughout 2026 as planned commercial initiatives seek to drive increasing awareness of CyPath® Lung ...

Cancer diagnostics company Pacific Edge (NZX/ASX: PEB) today notes that a draft Local Coverage Determination (LCD) with foundational medical policy for urine-based biomarkers for hematuria evaluation ...

Cancer diagnostics company Pacific Edge Limited (Pacific Edge or the Company) (NZX/ASX: PEB) today announces it has successfully raised NZ$25.4 million of new equity in a placement of new ordinary ...